JP2007503432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007503432A5 JP2007503432A5 JP2006524604A JP2006524604A JP2007503432A5 JP 2007503432 A5 JP2007503432 A5 JP 2007503432A5 JP 2006524604 A JP2006524604 A JP 2006524604A JP 2006524604 A JP2006524604 A JP 2006524604A JP 2007503432 A5 JP2007503432 A5 JP 2007503432A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- formula
- compound
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- -1 2-furylmethoxy Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 125000001153 fluoro group Chemical group F* 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 229910052717 sulfur Chemical group 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 8
- 125000005842 heteroatoms Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 239000001301 oxygen Chemical group 0.000 claims 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- 239000011593 sulfur Chemical group 0.000 claims 6
- 125000003302 alkenyloxy group Chemical group 0.000 claims 5
- 125000005133 alkynyloxy group Chemical group 0.000 claims 5
- 102000009410 chemokine receptors Human genes 0.000 claims 4
- 108050000299 chemokine receptors Proteins 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 3
- 229920000728 polyester Polymers 0.000 claims 3
- MDHKLBPWPXQBRH-UHFFFAOYSA-N 2,3-dichloro-N-(2-methoxypyrido[2,3-b]pyrazin-3-yl)benzenesulfonamide;2,3-dichloro-N-(3-methoxypyrido[2,3-b]pyrazin-2-yl)benzenesulfonamide;2,3-dichloro-N-(3,6,7-trimethoxyquinoxalin-2-yl)benzenesulfonamide Chemical compound COC1=NC2=CC=CN=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl.COC1=NC2=NC=CC=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl.COC=1N=C2C=C(OC)C(OC)=CC2=NC=1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl MDHKLBPWPXQBRH-UHFFFAOYSA-N 0.000 claims 2
- FDQKLKSLDWVXLG-UHFFFAOYSA-N 2,3-dichloro-N-(3-methoxypyrido[3,4-b]pyrazin-2-yl)benzenesulfonamide Chemical compound COC1=NC2=CN=CC=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl FDQKLKSLDWVXLG-UHFFFAOYSA-N 0.000 claims 2
- NHGRPSRQLPHEMF-UHFFFAOYSA-N 2,3-dichloro-N-(3-methoxyquinoxalin-2-yl)benzenesulfonamide Chemical compound COC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl NHGRPSRQLPHEMF-UHFFFAOYSA-N 0.000 claims 2
- OANFATXFRQSVOV-UHFFFAOYSA-N 2,3-dichloro-N-(6,7-dichloro-3-methoxyquinoxalin-2-yl)benzenesulfonamide Chemical compound COC1=NC2=CC(Cl)=C(Cl)C=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl OANFATXFRQSVOV-UHFFFAOYSA-N 0.000 claims 2
- KUALZWIOMOLXFZ-UHFFFAOYSA-N 5-chloro-N-(3-methoxyquinoxalin-2-yl)thiophene-2-sulfonamide;2,3-dichloro-N-(3,7-dimethoxyquinoxalin-2-yl)benzenesulfonamide Chemical compound COC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=C(Cl)S1.N=1C2=CC(OC)=CC=C2N=C(OC)C=1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl KUALZWIOMOLXFZ-UHFFFAOYSA-N 0.000 claims 2
- BRTQKDSZTUTDGQ-UHFFFAOYSA-N N-(3-methoxyquinoxalin-2-yl)-4-methylbenzenesulfonamide;N-(3-methoxyquinoxalin-2-yl)thiophene-2-sulfonamide Chemical compound COC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CS1.COC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=C(C)C=C1 BRTQKDSZTUTDGQ-UHFFFAOYSA-N 0.000 claims 2
- JPHVJWNFBPOISP-UHFFFAOYSA-N N-(7-bromo-2-methoxypyrido[2,3-b]pyrazin-3-yl)-2,3-dichlorobenzenesulfonamide Chemical compound COC1=NC2=CC(Br)=CN=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl JPHVJWNFBPOISP-UHFFFAOYSA-N 0.000 claims 2
- JXTKYWDKKKCMSZ-UHFFFAOYSA-N N-(7-bromo-3-methoxypyrido[2,3-b]pyrazin-2-yl)-2,3-dichlorobenzenesulfonamide Chemical compound COC1=NC2=NC=C(Br)C=C2N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1Cl JXTKYWDKKKCMSZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000000240 adjuvant Effects 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 102000004498 CCR4 Receptors Human genes 0.000 claims 1
- 108010017317 CCR4 Receptors Proteins 0.000 claims 1
- MDPCPLUKDJWCIZ-UHFFFAOYSA-N N-(3-chloroquinoxalin-2-yl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1Cl MDPCPLUKDJWCIZ-UHFFFAOYSA-N 0.000 claims 1
- NQMQRGNWHJIWHW-UHFFFAOYSA-N N-(3-chloroquinoxalin-2-yl)benzenesulfonamide Chemical compound ClC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 NQMQRGNWHJIWHW-UHFFFAOYSA-N 0.000 claims 1
- GRGHJRZOEBSNLB-UHFFFAOYSA-N N-(3-methoxyquinoxalin-2-yl)benzenesulfonamide Chemical compound COC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 GRGHJRZOEBSNLB-UHFFFAOYSA-N 0.000 claims 1
- NKINKNYHHBSAHN-UHFFFAOYSA-N N-[3-(furan-2-ylmethoxy)quinoxalin-2-yl]thiophene-2-sulfonamide Chemical compound C=1C=CSC=1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1OCC1=CC=CO1 NKINKNYHHBSAHN-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 claims 1
- 0 *c1nc(****2)c2nc1N Chemical compound *c1nc(****2)c2nc1N 0.000 description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- RVXKHAITGKBBAC-SFHVURJKSA-N N-[(1S)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine Chemical compound C([C@H](NC=1OC2=CC=C(C=C2N=1)C)C=1N=CC=CC=1)C1CCCCC1 RVXKHAITGKBBAC-SFHVURJKSA-N 0.000 description 1
- 229950010666 Ontazolast Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N Pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960004764 Zafirlukast Drugs 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- YKGCCFHSXQHWIG-UHFFFAOYSA-N phenothiazin-3-one Chemical class C1=CC=C2SC3=CC(=O)C=CC3=NC2=C1 YKGCCFHSXQHWIG-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229960001663 sulfanilamide Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302304A SE0302304D0 (sv) | 2003-08-27 | 2003-08-27 | Novel compounds |
| PCT/SE2004/001227 WO2005021513A1 (en) | 2003-08-27 | 2004-08-25 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treatment of chemokine mediated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007503432A JP2007503432A (ja) | 2007-02-22 |
| JP2007503432A5 true JP2007503432A5 (US07846941-20101207-C00217.png) | 2007-08-16 |
Family
ID=28673200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524604A Pending JP2007503432A (ja) | 2003-08-27 | 2004-08-25 | 新規な縮合ｎ−ピラジニル−スルホンアミドおよびケモカイン介在疾患の処置におけるそれらの使用 |
Country Status (8)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI328007B (en) * | 2002-01-16 | 2010-08-01 | Astrazeneca Ab | Novel compounds |
| JPWO2005023771A1 (ja) | 2003-09-05 | 2006-11-02 | 小野薬品工業株式会社 | ケモカインレセプターアンタゴニストおよびその医薬用途 |
| KR20140033237A (ko) | 2005-10-07 | 2014-03-17 | 엑셀리시스, 인코포레이티드 | 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법 |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| US20090182140A1 (en) * | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
| EP1956009A1 (en) * | 2005-12-02 | 2008-08-13 | Mitsubishi Tanabe Pharma Corporation | Aromatic compound |
| TW200730512A (en) * | 2005-12-12 | 2007-08-16 | Astrazeneca Ab | Novel compounds |
| BRPI0808013A2 (pt) * | 2007-02-22 | 2014-06-17 | Merck Serono Sa | Compostos de quinoxalina e uso dos mesmos |
| US7940543B2 (en) * | 2008-03-19 | 2011-05-10 | Nanya Technology Corp. | Low power synchronous memory command address scheme |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| US8673908B2 (en) | 2008-11-10 | 2014-03-18 | Kyowa Hakko Kirin Co., Ltd. | Kynurenine production inhibitor |
| TWI535442B (zh) | 2010-05-10 | 2016-06-01 | Kyowa Hakko Kirin Co Ltd | A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine |
| CN103270027A (zh) * | 2010-10-20 | 2013-08-28 | 默克雪兰诺日内瓦有限公司 | 制备取代的n-(3-氨基-喹喔啉-2-基)-磺酰胺和它们的中间体n-(3-氯-喹喔啉-2-基)-磺酰胺的方法 |
| JP6047497B2 (ja) * | 2011-11-09 | 2016-12-21 | 協和発酵キリン株式会社 | 含窒素複素環化合物 |
| KR101102377B1 (ko) * | 2011-11-11 | 2012-01-05 | 주식회사 에네스코 | 터빈로터 초음파 탐상용 스캐너 |
| WO2024048615A1 (ja) * | 2022-08-30 | 2024-03-07 | 協和キリン株式会社 | キノキサリン誘導体の製造方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1135471B (de) * | 1960-07-30 | 1962-08-30 | Basf Ag | Verfahren zur Herstellung von 3-Chlorchinoxalinderivaten |
| BE611822A (US07846941-20101207-C00217.png) * | 1960-12-21 | |||
| NL135386C (US07846941-20101207-C00217.png) * | 1966-08-08 | |||
| CS156880B1 (US07846941-20101207-C00217.png) * | 1972-02-09 | 1974-08-23 | ||
| DE3686688T2 (de) * | 1985-06-24 | 1993-03-18 | Merck & Co Inc | Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten. |
| US5529999A (en) * | 1994-03-04 | 1996-06-25 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| AUPN842196A0 (en) * | 1996-03-05 | 1996-03-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| DE60207890T2 (de) * | 2001-12-18 | 2006-08-10 | Astrazeneca Ab | Neue verbindungen |
| TWI328007B (en) * | 2002-01-16 | 2010-08-01 | Astrazeneca Ab | Novel compounds |
| US20060004010A1 (en) * | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
-
2003
- 2003-08-27 SE SE0302304A patent/SE0302304D0/xx unknown
-
2004
- 2004-08-25 JP JP2006524604A patent/JP2007503432A/ja active Pending
- 2004-08-25 EP EP04775333A patent/EP1660461B1/en not_active Expired - Lifetime
- 2004-08-25 WO PCT/SE2004/001227 patent/WO2005021513A1/en active Application Filing
- 2004-08-25 DE DE602004017332T patent/DE602004017332D1/de not_active Expired - Fee Related
- 2004-08-25 ES ES04775333T patent/ES2314445T3/es not_active Expired - Lifetime
- 2004-08-25 AT AT04775333T patent/ATE411984T1/de not_active IP Right Cessation
- 2004-08-25 US US10/570,178 patent/US20070093491A1/en not_active Abandoned
